SOM Biotech SL
SOM: The Drug Reprofiling Company focused on Rare Diseases
Raúl Insa. CEO
Address: Barcelona Science Park. Baldiri Reixac, 4
City: 08028 Barcelona
Province: Barcelona
Phone: 34 934020150
Mobile Phone: 34 690623263
Fax: 34 934034510
Mission and Objectives
SOM Biotech is a private global company focused in drug repurposing. It was established in 2010 at the Barcelona Science Park based in a property chemical field scaffold hopping technology with unlimited scalability. Our goals achieved up to day are:
- Repurposed compound SOM0226 indicated for any form of TTR Amyloidosi: Licensed-out (2016)
- Repurposed compound for SOM3355 indicated for Huntington's disease: Phase 2a ongoing.
- Several pre-clinical programs ongoing.
- 8 patents filed
Products/Services, Areas of interest for future collaborations/Alliances
We have discovered, developed, patented and licensed SOM0226; an orphan disease compound for TTR Amyloidosis, in all its forms (neuropathic, cardiac, senile and CNS form).
More than 20 compounds are in preclinical development for other indications:
- Huntington's disease (PoC ongoing)
- Adrenoleukodystrophy (PoC TBD)
- Duchenne
- Glioblastoma, etc
SOM has submitted 8 patents up to now and has the ability and structure to repurpose 25 projects per year, with the aim of submitting at least 6 more patents and license compounds mainly after Phase II proof of concept.

SOM Biotech SL
Developed by Web4Bio